HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$0.81 USD
-0.04 (-5.16%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.80 -0.01 (-0.76%) 6:26 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
HOOK 0.81 -0.04(-5.16%)
Will HOOK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HOOK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOOK
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
HOOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for February 2nd
Other News for HOOK
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
Hookipa Pharma Announces Major HB-200 Clinical Trial Design
Hookipa Pharma announces Phase 2/3 trial design for HB-200
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Hookipa Pharma announces FDA clearance of IND application for HB-700